In a recent development, Jefferies analyst Dennis Ding has initiated coverage on Mineralys Therapeutics (MLYS, Financial), a company listed on NASDAQ. The coverage comes with a 'Hold' rating, signaling a neutral stance on the stock.
The price target set for Mineralys Therapeutics (MLYS, Financial) is USD 15.00, which remains unchanged since this is the first time Jefferies has covered the stock. This target reflects the analyst's expectations based on current evaluations and market conditions.
As of June 11, 2025, investors and market watchers will be closely observing the stock's movements to see how it aligns with Jefferies' assessment. The announcement provides insight into the firm's perspective on MLYS's market position and potential growth trajectory.
Mineralys Therapeutics (MLYS, Financial) continues to be a point of interest for investors looking for reliable assessments and expert opinions to guide their investment decisions. The 'Hold' rating suggests that Jefferies anticipates steady performance from the company at present.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Mineralys Therapeutics Inc (MLYS, Financial) is $36.25 with a high estimate of $48.00 and a low estimate of $15.00. The average target implies an upside of 126.14% from the current price of $16.03. More detailed estimate data can be found on the Mineralys Therapeutics Inc (MLYS) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Mineralys Therapeutics Inc's (MLYS, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
